N-803 (Anktiva)

N-803 · ImmunityBio, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for N-803 (Anktiva), covering 2026-02-12 to 2026-02-12. Get the full timeline:

Most recent: Clinical Trial Update: N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma [Phase 2]